Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Chromosome 5q Deletion Syndrome 1Blast Crisis 1

Interventions

merphos 3Tacrolimus 3Methotrexate 3Peripheral Blood Stem Cell Transplantation 2Flow Cytometry 2Cytogenetic Analysis 2Cyclosporine 2Cyclophosphamide 2Busulfan 2fludarabine phosphate 1adavosertib 1Whole-Body Irradiation 1Vorinostat 1Sunitinib 1Pharmacogenomic Testing 1Mycophenolic Acid 1In Situ Hybridization, Fluorescence 1Enzyme-Linked Immunosorbent Assay 1Deferasirox 1Cytarabine 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromosome 5q Deletion Syndrome × adavosertib × Myeloid × Clear all
NCT02666950 2019-09-06

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Mayo Clinic

Phase 2 Completed
3 enrolled 11 charts
MyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡